Arthritis Research & Therapy最新文献

{"title":"Early risk stratification in lupus nephritis based on established prognostic factors: association with outcomes under triple therapy.","authors":"Hironari Hanaoka, Ryota Sakai, Takumi Aoki, Yuri Sasaki, Taiji Kosaka, Shoichi Yoshinaga, Akiko Shibata, Takahiko Kurasawa, Koichi Amano","doi":"10.1186/s13075-026-03876-w","DOIUrl":"10.1186/s13075-026-03876-w","url":null,"abstract":"<p><strong>Background: </strong>To apply the 2025 EULAR prognostic factors to identify subgroups of patients with lupus nephritis (LN) in which triple therapy was associated with higher complete renal response (CR) rates.</p><p><strong>Methods: </strong>We conducted a medical record review of patients with biopsy-proven class III, IV, or V LN who were treated at our hospital between 2000 and 2024. Multivariate logistic regression was used to identify EULAR 2025 prognostic factors independently associated with CR. Patients were stratified according to major prognostic factors and the cumulative burden of additional factors. Cumulative CR rates were compared, and Cox proportional hazards models were applied to evaluate the association between risk stratification and CR.</p><p><strong>Results: </strong>Among the 170 patients included in this study, nephrotic-range proteinuria and a history of previous LN flare were negatively associated with CR (odds ratio [OR] 0.25, 95% confidence interval [CI] 0.11-0.55, p < 0.01 and OR 0.29, 95% CI 0.12-0.65, p < 0.01, respectively). Using a stepwise risk stratification approach incorporating these factors and the cumulative number of remaining prognostic factors, patients were classified into low-, moderate-, and high-risk groups, showing a clear gradient in CR rates (94.0% vs. 71.8% vs. 40.9%, respectively, p < 0.01). Using the high-risk group as the reference, the likelihood of achieving CR was substantially higher in the low- and moderate-risk groups (hazard ratio [HR] 22.8, 95% CI 8.27-81.24, p < 0.01 and HR 3.7, 95% CI 1.53-9.52, p = 0.01). In the high-risk group, triple therapy remained independently associated with CR (adjusted HR 3.13, 95% CI 1.17-8.73, p = 0.02).</p><p><strong>Conclusions: </strong>These findings suggest that baseline risk stratification identified subgroups in which triple therapy was associated with higher CR rates. Prospective validation in independent cohorts is required before this approach can inform treatment selection.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13523271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roflumilast mitigates cartilage degeneration in osteoarthritis by activating CFTR-mediated anti-apoptotic signaling.","authors":"Haoyu Yang, Guihua Tan, Xunhao Wang, Nuo Xu, Wenli Gong, Ruiyang Jiang, Xiaoyu Jin, Chenfeng Qiao, Zhaofeng Zhang, Gang Zhao, Dongquan Shi, Jingyi Mi","doi":"10.1186/s13075-026-03872-0","DOIUrl":"10.1186/s13075-026-03872-0","url":null,"abstract":"<p><p>Osteoarthritis (OA) is a chronic degenerative joint disorder marked by progressive cartilage loss, synovial inflammation, and remodeling of the subchondral bone. Although roflumilast, a selective phosphodiesterase-4 inhibitor, has shown clinical benefits in chronic inflammatory diseases, its potential role in OA has not been defined. Here, we examined whether roflumilast can protect chondrocytes against apoptosis and extracellular matrix (ECM) degradation under inflammatory stress. In IL-1β-stimulated primary chondrocytes, roflumilast pretreatment (20 µM) suppressed the expression of matrix-degrading enzymes MMP13 and ADAMTS5, while restoring collagen II and aggrecan, thereby maintaining ECM integrity. Transcriptomic profiling identified a strong upregulation of cystic fibrosis transmembrane conductance regulator (CFTR) alongside the suppression of apoptosis-related genes. Mechanistically, roflumilast activated the Akt/Bcl-2 signaling cascade, and either pharmacological blockade or siRNA silencing of CFTR abolished these protective effects, indicating a CFTR-dependent pathway. Consistently, human OA cartilage displayed a marked reduction in CFTR expression, underscoring the clinical relevance of this mechanism. In vivo, roflumilast treatment in the destabilization of the medial meniscus mouse model alleviated cartilage erosion, improved subchondral bone architecture, and reduced synovial inflammation. Behavioral and imaging assessments further confirmed enhanced locomotor performance and mitigated joint degeneration. Collectively, our findings identify CFTR as a crucial mediator of roflumilast-induced chondroprotection and highlight roflumilast as a promising candidate for disease modification in OA.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13681766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149222954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CYBB regulates synovial fibroblast inflammatory activation and sEV-mediated synovial-cartilage communication in osteoarthritis.","authors":"Kai Chen, Xiaoyu Dai, Peizhen Wang, Chuyi Wang, Chang Lv, Huaqiang Tao, Dechun Geng, Wenge Ding, Shujun Lv","doi":"10.1186/s13075-026-03866-y","DOIUrl":"10.1186/s13075-026-03866-y","url":null,"abstract":"<p><strong>Objective: </strong>Although synovial inflammation is recognized as a factor in the progression of osteoarthritis (OA), the specific role of fibroblast-like synoviocytes (FLS) in cartilage degradation has yet to be fully elucidated. This study sought to identify key regulators that connect inflammatory FLS to chondrocyte dysfunction.</p><p><strong>Methods: </strong>An integrated re-analysis of bulk and single-cell RNA sequencing data from OA synovial tissues was conducted to identify consistently upregulated genes. Functional assays, including migration and invasion tests, were performed on inflammatory FLS. FLS with silenced CYBB expression were co-cultured with chondrocytes to evaluate paracrine effects. small extracellular vesicle (sEV) isolation and tracking were utilized to assess intercellular communication. An OA rat model was employed for in vivo validation through local CYBB knockdown.</p><p><strong>Results: </strong>CYBB expression was markedly upregulated in OA synovium, particularly within inflammatory FLS. Inhibition of CYBB reduced FLS inflammation, migration, and invasion. In co-culture experiments, inflammatory FLS induced chondrocyte inflammation and disrupted matrix gene expression in a manner dependent on CYBB. These effects were mediated by sEVs derived from fibroblast-like synoviocytes (FLS), with their inflammatory cargo being modified through CYBB silencing. In vivo experiments demonstrated that localized suppression of CYBB alleviated synovitis and cartilage degeneration.</p><p><strong>Conclusions: </strong>CYBB serves as a pivotal mediator linking synovial inflammation to cartilage damage in osteoarthritis (OA), by mechanistically regulating the sEV-mediated communication from FLS to chondrocytes. Targeting CYBB could potentially represent a novel therapeutic strategy for OA.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13679134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149219762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minor salivary gland biopsies in childhood-onset Sjögren's disease show greater inflammation and more frequent fibrotic changes than in adult-onset Sjögren's disease.","authors":"Flavia Riccio, Silvana Ancona, Vincenzo Luca Lentini, Jacopo Ferro, Valerio Gaetano Vellone, Nicola Laffi, Enrico Tirri, Marco Gattorno, Aroldo Rizzo, Francesco Ciccia, Clara Malattia, Saviana Gandolfo","doi":"10.1186/s13075-026-03871-1","DOIUrl":"10.1186/s13075-026-03871-1","url":null,"abstract":"<p><strong>Objectives: </strong>To provide the first histopathological characterization of minor salivary gland (MSG) biopsies in childhood-onset Sjögren's disease (cSjD) in comparison with adult Sjögren's disease (SjD).</p><p><strong>Methods: </strong>MSG biopsies obtained by eighteen consecutive children fulfilling the 2016 ACR/EULAR classification criteria for SjD and 55 consecutive adult SjD patients were analysed. Clinical features, ESSDAI, ESSPRI, and salivary gland histopathology were collected according to EULAR standards, including focus score (FS), lymphoepithelial lesions (LELs), and ectopic germinal centers (GCs) by immunohistochemistry.</p><p><strong>Results: </strong>Compared with adults, children showed a more inflammatory phenotype. Recurrent parotid swelling was significantly more frequent in cSjD (38.9% vs. 5.5%, p = 0.0015), whereas xerostomia and xerophthalmia predominated in adults (p < 0.0001 for both). Palpable purpura was more common in children (44.4% vs. 1.8%, p < 0.0001), while fatigue and myalgia were rare (p = 0.0058 and p < 0.0001, respectively). Rheumatoid factor was more prevalent in cSjD (77.7% vs. 30.9%, p = 0.0072), whereas anti-SSA antibodies were less frequent (p = 0.0029). ESSDAI scores were higher (p = 0.0001) and ESSPRI lower (p < 0.0001) in children, reflecting greater systemic inflammation but lower subjective symptom burden. Pediatric biopsies exhibited higher FS than adults (median 3.4 vs. 1.0, p = 0.0002), together with more frequent GCs (44.4% vs. 5.5%, p = 0.00034), LELs (61.1% vs. 5.5%, p < 0.0001), and fibrotic changes (66.7% vs. 27.3%, p = 0.0048). Quantitative immunohistochemistry further showed significantly increased CD3 and CD20 lymphocytic infiltrates in cSjD biopsies, together with an increased CD20/(CD20 + CD3) proportion (all p < 0.0001).</p><p><strong>Conclusions: </strong>MSG biopsies in cSjD show a more inflammatory, lymphoid-organizing B-enriched phenotype, with more frequent fibrosis than in adults. These findings are in keeping with previous observations in pediatric parotid tissue and highlight frequent fibrotic remodelling alongside marked inflammation despite shorter disease duration in children.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-dependent effects of TRPA1 deficiency on pain and osteoarthritis pathology following joint injury in mice.","authors":"Karsyn N Bailey, Erika Barboza Prado Lopes, Farshid Guilak, Timothy M Griffin","doi":"10.1186/s13075-026-03868-w","DOIUrl":"10.1186/s13075-026-03868-w","url":null,"abstract":"<p><strong>Introduction: </strong>Transient receptor potential ankyrin 1 (TRPA1) is a calcium-permeable cation channel expressed in multiple cell types, including nociceptive C-fibers innervating the knee joint, and is activated by mechanical, inflammatory, and oxidative stimuli. While TRPA1 inhibition reduces pain-related behavior in chemically-induced arthritis, its role in mechanically induced osteoarthritis (OA), and how this relationship changes with age, remains unclear. Here we tested the hypothesis that TRPA1 deficiency alters mechanical sensitivity and OA pathology after joint injury in an age-dependent manner in mice.</p><p><strong>Methods: </strong>Male C57BL/6J wildtype (WT) and TRPA1-deficient (TRPA1^-/-) mice underwent unilateral destabilization of the medial meniscus (DMM) at either 14 weeks (young) or 48 weeks (adult) of age. Mechanical sensitivity was assessed weekly for 7 weeks using von Frey testing. In young mice, gait biomechanics were measured with a force-instrumented running wheel, and voluntary cage activity and energy expenditure were assessed before and after DMM. At 8 weeks post-injury, histologic analyses were performed to evaluate cartilage degeneration and osteophyte formation.</p><p><strong>Results: </strong>In young mice, TRPA1^-/- mice exhibited higher 50% paw-withdrawal thresholds than WT mice at 1 and 3 weeks after DMM (p < 0.05), consistent with reduced early mechanical hypersensitivity. However, TRPA1^-/- mice showed more severe cartilage degeneration and osteophyte formation in the injured medial compartment (p < 0.05) and altered gait biomechanics after injury (p < 0.05). In adult mice, TRPA1 deficiency did not significantly alter OA pathology or withdrawal thresholds, although trends toward genotype differences were observed at select post-injury timepoints. Across genotypes, older mice displayed less hypersensitivity following DMM than younger mice.</p><p><strong>Conclusions: </strong>TRPA1 contributes to early post-injury mechanical sensitivity and gait mechanics following joint injury. TRPA1 deficiency results in altered gait biomechanics and more severe OA development in young mice but not in adult mice. These findings indicate an age-dependent interaction between sensory signaling and joint degeneration, with implications for TRPA1-targeted analgesic strategies in joint disease.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149219785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulated IL-6 pathway activity in idiopathic inflammatory myopathies.","authors":"Anja Srpčič, Felicita Urzi, Manca Ogrič, Mojca Frank Bertoncelj, Saša Čučnik, Polonca Mali, Sergej Pirkmajer, Katja Lakota, Katja Perdan Pirkmajer","doi":"10.1186/s13075-026-03867-x","DOIUrl":"10.1186/s13075-026-03867-x","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to characterise interleukin-6 (IL-6) pathway activity in idiopathic inflammatory myopathies (IIM) and investigate the contribution of circulating IL-6, soluble IL-6 receptor (sIL-6R) and anti-IL-6 autoantibodies to systemic IL-6 signalling.</p><p><strong>Methods: </strong>IL-6 pathway activity was assessed in skeletal muscle transcriptomic data from patients with IIM and healthy controls. Serum samples from 51 patients with IIM and 32 controls were analysed for IL-6, sIL-6R and anti-IL-6 autoantibodies by ELISA. The capacity of serum to modulate IL-6 signalling in serum was quantified using a reporter gene assay (RGA).</p><p><strong>Results: </strong>Transcriptomic analysis revealed enrichment of IL-6/JAK/STAT3 signalling in IIM muscle tissue across disease subtypes. Serum IL-6 levels were increased in IIM, while sIL-6R concentrations were comparable to those in controls. In contrast, anti-IL-6 autoantibody levels were reduced, particularly in dermatomyositis. Despite variability in individual components, serum from patients with IIM induced markedly increased IL-6 signalling activity in the RGA compared with controls. This enhanced signalling was independent of endogenous IL-6 concentrations and persisted in treated patients. Anti-IL-6 autoantibodies displayed moderate-to-high avidity and demonstrated neutralising capacity in vitro. Increased IL-6 signalling activity showed a negative association trend with muscle strength in newly diagnosed patients.</p><p><strong>Conclusions: </strong>IIM is characterised by enhanced systemic IL-6 pathway activity that is not explained by circulating IL-6 levels alone but rather reflects a dysregulated cytokine milieu. Reduced levels of endogenous anti-IL-6 autoantibodies, together with their neutralising capacity, suggest a potential role in modulating IL-6 bioactivity.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148547730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of first-line biologic immunomodulation compared with non-biologic therapies in adult-onset Still's disease: a two-center cohort study.","authors":"Ruru Guo, Xuesong Liu, Yixuan Li, Yi Qin, Xinyu Li, Georg Schett, Liyang Gu, Jürgen Rech, Liangjing Lu","doi":"10.1186/s13075-026-03861-3","DOIUrl":"10.1186/s13075-026-03861-3","url":null,"abstract":"<p><strong>Background: </strong>To evaluate comparative effectiveness of methotrexate (MTX), calcineurin inhibitors (CNI), Janus kinase inhibitors (JAKi), and biologics for the first-line therapies in adult-onset Still's disease (AOSD) in real-world settings.</p><p><strong>Methods: </strong>Two AOSD cohorts were retrospectively analysed. First, effectiveness of first-line biological versus non-biologic modulator was validated using overlap weighting of propensity scores in the Shanghai AOSD cohort. To compare AOSD treatment strategies (MTX, CNI, JAKi, biologics), we pooled data from the Shanghai and Erlangen cohorts, emulated a target trial, and applied doubly robust weighted regression to adjust for demographic and clinical confounders. The primary outcome was sustained event-free remission over 12 and 72 weeks.</p><p><strong>Results: </strong>124 AOSD patients were analyzed, 96 from the Shanghai and 28 from Erlangen cohort. In overlap-weighted analyses of Shanghai cohort, biologic was associated with higher sustained event-free remission and event-free state than non-biologic immune modulators (P = 0.0065 and P = 0.0096). In the pooled analysis, biologics were linked to higher likelihood of event-free state and sustained event-free remission at weeks 12 and 72 (all P < 0.05). Pairwise comparisons confirmed the advantage of biologics over CNI (sustained event-free remission at week 72 OR 0.11, p = 0.001), with significant benefits over MTX (OR 0.12, p = 0.002) and JAKi (OR 0.14, p = 0.008) emerging at week 72 for sustained event-free remission, and more frequent glucocorticoid discontinuation than MTX and CNI (both p < 0.05).</p><p><strong>Conclusions: </strong>First-line biological treatment is associated with improved sustained event-free remission compared to non-biologic treatments, such as MTX, CNI and JAKi and associated with more favorable long-term outcomes in AOSD.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148534832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis.","authors":"Anna Ef Hadsbjerg, Simon Krabbe, Nora Vladimirova, Adrian Ciurea, Kristýna Bubová, Monika Gregová, Michael J Nissen, Burkhard Möller, Raphael Micheroli, Susanne J Pedersen, Jakub Závada, Ziga Snoj, Karlo Pintaric, Bjorn Gudbjornsson, Ziga Rotar, Iris Eshed, Iwona Sudol-Szopinska, Kasper Gosvig, Torsten Diekhoff, Robert Gw Lambert, Manouk de Hooge, Jakob M Møller, Karel Gorican, Marie Wetterslev, Stephanie Wichuk, Maurice Donzallaz, Alexander Bernatschek, Stylianos Georgiadis, Merete Lund Hetland, Lykke M Ørnbjerg, Mikkel Østergaard","doi":"10.1186/s13075-026-03865-z","DOIUrl":"10.1186/s13075-026-03865-z","url":null,"abstract":"<p><strong>Background: </strong>According to the modified New York criteria (mNYc), moderate-severe sacroiliac joint (SIJ) structural damage on radiography is necessary for classifying radiographic axial spondyloarthritis (r-axSpA). In contrast to radiography, MRI provides no ionizing radiation, higher sensitivity for structural damage, better inter-reader reliability, and is gradually replacing radiography. Therefore, we aimed to develop and validate a high specificity MRI cut-off to the radiographic component of the mNYc (rad-mNYc), defined as MRI findings that correspond to an mNY-positive radiograph.</p><p><strong>Methods: </strong>Patients diagnosed with axSpA with available SIJ MRI and radiograph from five European clinical registries in the EuroSpA Collaboration were included. MRIs were read according to the SPARCC structural score (based on 5 predefined or all slices) and radiographs the rad-mNYc. Cut-offs with 95% specificity for rad-mNYc-positivity for MRI sum scores for individual lesions and for an MRI SIJ hierarchical Composite Structural Damage Score (CSDS₅/CSDS_all based on erosion, backfill and ankylosis in 5/all slices) and ROC curves were calculated. Internal validation by bootstrapping was performed.</p><p><strong>Results: </strong>Overall, 640 patients were included; 296 (46%) were rad-mNYc positive. The 95%-specificity cut-off was ≥ 30 for the composite score CSDS₅ predicting rad-mNYc (specificity 0.95, sensitivity 0.39, area-under-curve 0.83, accuracy with mNYc 69.2%. Internal validation showed moderate accuracy and high positive predictive value. Cut-offs for sclerosis, erosion, backfill and ankylosis were ≥ 9, ≥12, ≥ 5, and ≥ 1, respectively, with sensitivities all ≤ 0.21 except ankylosis 0.34 and accuracy ~ 60%, except ankylosis 67%. Cut-offs using all MRI-slices performed slightly worse or similarly.</p><p><strong>Conclusions: </strong>A composite MRI-score based on assessing erosion, backfill and ankylosis for five predefined semicoronal SIJ slices (CSDS₅) was the optimal high specificity MRI cut-off to rad-mNYc positivity, being potentially usable in both research and clinical settings, with different thresholds depending on whether sensitivity or specificity is prioritized.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13656707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148468549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab.","authors":"Nora Vladimirova, Mikkel Østergaard, Stylianos Georgiadis, Sengül Seven, Jakob M Møller, Bente Jensen, Rene Østgård, Rene Poggenborg, Ole Rintek Madsen, Oliver Hendricks, Lau Brix, Susanne Juhl Pedersen","doi":"10.1186/s13075-026-03862-2","DOIUrl":"10.1186/s13075-026-03862-2","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148468657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct cytokine and chemokine alterations in bronchoalveolar fluid from patients with systemic juvenile idiopathic arthritis associated lung disease (SJIA-LD).","authors":"Ivanna Romankevych, Alyssa Sproles, Thuy Do, Lexi Auld, Taskin Sabit, Richard Chhaing, Elizabeth Baker, Ashish Kumar, Bruce Trapnell, Brenna Carey, John J Brewington, Christopher Towe, Alexei Grom, Grant Schulert","doi":"10.1186/s13075-026-03863-1","DOIUrl":"10.1186/s13075-026-03863-1","url":null,"abstract":"<p><strong>Background: </strong>Lung disease associated with systemic juvenile idiopathic arthritis (SJIA-LD) remains poorly understood. Evaluation of bronchoalveolar lavage fluid (BALF) may better reflect disease pathogenesis. The objectives of our study were to measure levels of cytokines and chemokines in BALF and their associations with clinical features and treatment in patients with SJIA-LD.</p><p><strong>Methods: </strong>Children with SJIA-LD undergoing clinically indicated diagnostic bronchoscopy were enrolled. Comparator BALF was collected from patients with other chronic inflammatory and non-inflammatory lung diseases. BALF was assayed for IL-6, 8 and 18, S100A8/9, S100A12, sCD25, CCL11, CCL17, CCL25, MMP7, and CXCL9.</p><p><strong>Results: </strong>BALF was obtained from 21 patients with SJIA-LD and 54 comparator patients with other lung diseases. Compared to all controls, children with SJIA-LD had a significant elevation of IL-18 (median (IQR) 1406 (722.3-2812) vs 37.2 (25.3-70) pg/mL, p < 0.0001), S100A8/9 (4745.3 (3003-11506) vs. 1297.5 (260-7755) ng/mL, p = 0.02), sCD25 (31.6 (19-50.3) vs. 13.6 (8.6-37.3) pg/mL, p = 0.04), MMP-7 (18,466.7 (10,462.2-33,516.1) vs. 13.645 (8.6-37.3) pg/mL, p = 0.0384), and CCL17 (0 (0-63.1; p = 0.038) vs 0 (0-0) pg/mL. BALF IL-18 was significantly higher in children with SJIA-LD compared to all control subgroups (inflammatory and non-inflammatory airway disease, autoimmune pulmonary alveolar proteinosis, and poorly controlled asthma), in patients who were actively treated with anti-cytokine biologics (N = 9), and in patients who ultimately underwent hematopoietic stem cell transfer (N = 8). Patients receiving anti-cytokine biologics also had significant elevations in several other cytokines compared to patients without such treatments, while profiles in those treated with JAKi (N = 14) were largely similar. Linear regression analysis showed an association between BALF level of IL-18 and the number of immunosuppressive medications utilized (p = 0.0167), but not with O2 requirement, dose of anakinra or prednisone, plasma IL-18, ferritin, CRP or ESR.</p><p><strong>Conclusions: </strong>Patients with SJIA-LD showed a distinct BALF cytokine profile, including significant IL-18, S100A8/9 protein, sCD25, and CCL-17 elevation. The level of IL-18 was higher in patients who required more immunosuppressive medications and were actively treated with anti-cytokine biologics. The relationship between BALF cytokine profiles and anti-cytokine biologics and JAK inhibitors is unclear and should be evaluated further.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13560383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148468554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}